Cargando…
Addition of metformin to non‐small‐cell lung cancer patients with or without diabetes
Autores principales: | Chen, Hua‐Fen, Lin, Rong, Hsu, Chen‐Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834688/ https://www.ncbi.nlm.nih.gov/pubmed/36450700 http://dx.doi.org/10.1111/1759-7714.14756 |
Ejemplares similares
-
Factors affecting long‐term survival of non‐small‐cell lung cancer patients with concomitant type 2 diabetes mellitus
por: Jiang, Ju‐Ying, et al.
Publicado: (2022) -
Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023) -
Comments on “dynamic
(18)F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer”
por: Wang, Shan‐Ying, et al.
Publicado: (2022) -
Reply to: Comment on ‘Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung’
por: Robinson, Lary A, et al.
Publicado: (2017) -
Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
por: Wang, Yan, et al.
Publicado: (2023)